All Products

Featured Products

Newest Products

Research Areas

Naloxegol Oxalate
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319933

CAS#: 1354744-91-4 (oxalate)

Description: Naloxegol, also known as and NKTR-118 and AZ-13337019, is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation. It was approved in 2014 in adult patients with chronic, non-cancer pain. Chemically, naloxegol is a pegylated (polyethylene glycol-modified) derivative of α-naloxol. Specifically, the 5-α-hydroxyl group of α-naloxol is connected via an ether linkage to the free hydroxyl group of a monomethoxy-terminated n=7 oligomer of PEG.


Price and Availability

Size
Price
25mg
USD 90
200mg
USD 450
2g
USD 3250
Size
Price
50mg
USD 150
500mg
USD 950
5g
USD 5450
Size
Price
100mg
USD 250
1g
USD 1750
10g
USD 8650

Naloxegol Oxalate, purity > 98%, is in stock. The same day shipping out after order is received. Note: the estimated shipping out time for order > 200mg may be 2 weeks.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 319933
Name: Naloxegol Oxalate
CAS#: 1354744-91-4 (oxalate)
Chemical Formula: C36H55NO15
Exact Mass:
Molecular Weight: 741.828
Elemental Analysis: C, 58.29; H, 7.47; N, 1.89; O, 32.35


Related CAS #: 1354744-91-4 (oxalate)   854601-70-0 (free base)  

Synonym: NKTR-118; NKTR 118; NKTR118; AZ-13337019; AZ13337019; AZ 13337019; EGylated naloxol; Naloxegol Oxalate; trade names Movantik and Moventig.

IUPAC/Chemical Name: (4R,4aS,7S,7aR,12bS)-7-((2,5,8,11,14,17,20-heptaoxadocosan-22-yl)oxy)-3-allyl-1,2,3,4,5,6,7,7a-octahydro-4aH-4,12-methanobenzofuro[3,2-e]isoquinoline-4a,9-diol oxalate

InChi Key: MNYIRXLCPODKLG-VUTNLTPYSA-N

InChi Code: InChI=1S/C34H53NO11.C2H2O4/c1-3-9-35-10-8-33-30-26-4-5-27(36)31(30)46-32(33)28(6-7-34(33,37)29(35)25-26)45-24-23-44-22-21-43-20-19-42-18-17-41-16-15-40-14-13-39-12-11-38-2;3-1(4)2(5)6/h3-5,28-29,32,36-37H,1,6-25H2,2H3;(H,3,4)(H,5,6)/t28-,29+,32-,33-,34+;/m0./s1

SMILES Code: O[C@@]12CC[C@H](OCCOCCOCCOCCOCCOCCOCCOC)[C@@]3([H])[C@@]14CCN(CC=C)[C@]2([H])CC5=C4C(O3)=C(O)C=C5.O=C(O)C(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View CoA: current batch, Lot#CRB70209

QC Data:
View QC data: current batch, Lot#CRB70209

Safety Data Sheet (MSDS):
View Material Safety Data Sheet (MSDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information


References

1: Al-Huniti N. Reply to: Letter to the Editor "Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol". J Clin Pharmacol. 2016 Apr;56(4):508. doi: 10.1002/jcph.674. PubMed PMID: 26954553.

2: Ruan X. The Effect of Quinidine, a Strong P-Glycoprotein Inhibitor, on the Pharmacokinetics and Central Nervous System Distribution of Naloxegol. J Clin Pharmacol. 2016 Apr;56(4):506-7. doi: 10.1002/jcph.651. PubMed PMID: 26954552.

3: Naloxegol (Movantik) for Opioid-Induced Constipation. JAMA. 2016 Jan 12;315(2):194-5. doi: 10.1001/jama.2015.17459. PubMed PMID: 26757469.

4: Bui K, Zhou D, Sostek M, She F, Al-Huniti N. Effects of CYP3A Modulators on the Pharmacokinetics of Naloxegol. J Clin Pharmacol. 2015 Dec 17. doi: 10.1002/jcph.693. [Epub ahead of print] PubMed PMID: 26678015.

5: ▼Naloxegol for opioid-induced constipation. Drug Ther Bull. 2015 Dec;53(12):138-40. doi: 10.1136/dtb.2015.12.0369. PubMed PMID: 26660436.

6: Tack J, Lappalainen J, Diva U, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. United European Gastroenterol J. 2015 Oct;3(5):471-80. doi: 10.1177/2050640615604543. PubMed PMID: 26535126; PubMed Central PMCID: PMC4625753.

7: Naloxegol (Movantik) for opioid-induced constipation. Med Lett Drugs Ther. 2015 Sep 28;57(1478):135-7. Review. PubMed PMID: 26393826.

8: Corsetti M, Tack J. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation. Drugs Today (Barc). 2015 Aug;51(8):479-89. doi: 10.1358/dot.2015.51.8.2364896. Review. PubMed PMID: 26380386.

9: Bui K, She F, Hutchison M, Brunnström Å, Sostek M. Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. Int J Clin Pharmacol Ther. 2015 Oct;53(10):838-46. doi: 10.5414/CP202276. PubMed PMID: 26329350; PubMed Central PMCID: PMC4564822.

10: Al-Huniti N, Chapel S, Xu H, Bui KH, Sostek M. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. Br J Clin Pharmacol. 2016 Jan;81(1):89-100. doi: 10.1111/bcp.12756. Epub 2015 Oct 27. PubMed PMID: 26317320; PubMed Central PMCID: PMC4693583.

11: Anantharamu T, Sharma S, Gupta AK, Dahiya N, Singh Brashier DB, Sharma AK. Naloxegol: First oral peripherally acting mu opioid receptor antagonists for opioid-induced constipation. J Pharmacol Pharmacother. 2015 Jul-Sep;6(3):188-92. doi: 10.4103/0976-500X.162015. PubMed PMID: 26312011; PubMed Central PMCID: PMC4544149.

12: Bui K, She F, Zhou D, Butler K, Al-Huniti N, Sostek M. The effect of quinidine, a strong P-glycoprotein inhibitor, on the pharmacokinetics and central nervous system distribution of naloxegol. J Clin Pharmacol. 2016 Apr;56(4):497-505. doi: 10.1002/jcph.613. Epub 2015 Nov 9. PubMed PMID: 26248047.

13: Hussar DA, Jeon MM. Naloxegol oxalate, pirfenidone, and nintedanib. J Am Pharm Assoc (2003). 2015 Jul-Aug;55(4):461-3. doi: 10.1331/JAPhA.2015.15523. PubMed PMID: 26161491.

14: Jones R, Prommer E, Backstedt D. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation. Am J Hosp Palliat Care. 2015 Jul 6. pii: 1049909115593937. [Epub ahead of print] PubMed PMID: 26150678.

15: Bruner HC, Atayee RS, Edmonds KP, Buckholz GT. Clinical utility of naloxegol in the treatment of opioid-induced constipation. J Pain Res. 2015 Jun 12;8:289-94. doi: 10.2147/JPR.S61326. eCollection 2015. Review. PubMed PMID: 26109876; PubMed Central PMCID: PMC4472065.

16: Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: removal of naloxegol from control. Final rule. Fed Regist. 2015 Jan 23;80(15):3468-70. PubMed PMID: 25730920.

17: Garnock-Jones KP. Naloxegol: a review of its use in patients with opioid-induced constipation. Drugs. 2015 Mar;75(4):419-25. doi: 10.1007/s40265-015-0357-2. Review. PubMed PMID: 25666542.

18: Corsetti M, Tack J. Naloxegol , a new drug for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2015 Feb;16(3):399-406. doi: 10.1517/14656566.2015.991306. Epub 2014 Dec 13. Review. PubMed PMID: 25496063.

19: Leonard J, Baker DE. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Ann Pharmacother. 2015 Mar;49(3):360-5. doi: 10.1177/1060028014560191. Epub 2014 Dec 3. Review. PubMed PMID: 25471070.

20: Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014 Sep 19;7:345-58. doi: 10.2147/CEG.S52097. eCollection 2014. Review. PubMed PMID: 25278772; PubMed Central PMCID: PMC4179399.